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Introduction
Anti-neutrophil cytoplasm antibody-associated vasculiti-
dies (AAV) represent a group of necrotizing small vessel
vasculitidies thati n c l u d eW e g e n e r ’s granulomatosis,
microscopic polyangiitis and Churg-Strauss-Syndrome.
To date, little is known regarding endothelial cell survival
and vessel regeneration in patients with AAV, despite the
increasingly recognised role of vascular endothelial
growth factor (VEGF) in mediating vessel repair.
Aim
Assess the role of sFlt1 in patients with AAV.
Material and methods
Were included 40 patients with PR3-AAV during active
disease (n=20) or remission (n=20) and 23 patients with
MPO-AAV during active disease (n=10) or remission
(n=13). Eighteen additional PR3-AAV patients had paired
serum samples drawn at the onset of the disease and at
three months of follow-up.
Results
Serum levels of soluble Flt1 (sFlt1), a potent inhibitor of
VEGF, are significantly increased during the acute phase
of PR3-AAV (2592 ± 11347 pg/ml) and MPO-AAV (476
± 4258 pg/ml) compared to controls (118 ± 269 pg/ml).
sFlt1 levels decreased during disease remission but
remained increased compared to controls in patients
with PR3-AAV. sFlt1 serum levels correlated with serum
levels of C5a, an anaphylatoxin released following
complement activation. Serum from patients with acute
PR3-AAV induced the release of sFlt1 by human mono-
cytes in vitro, but failed to induce a similar effect on
endothelial cells. Pre-treatment of monocytes with an
anti-C5a receptor blocking antibody attenuated sFlt1
release. Serum from patients with acute AAV induced a
disruption of blood flow in the chicken chorioallantoic
membrane assay and this effect was prevented by incu-
bating patients’ serum with an excess of human VEGF.
Conclusion
Our data indicate that a complement mediated-increase
in sFlt1 occurs during acute AAV which leads to an “anti-
angiogenic” state that hinders endothelial repair. “Pro-
angiogenic” therapies, which would include complement
activation inhibitors, may enhance endothelial repair dur-
ing AAV and thus reduce renal vascular scarring.
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